Ann: Half Yearly Report and Accounts, page-2

You would assume the Glaxo phase 1 trial in ulcerative colitis had a good outcome with Ph 2 continuing and paid for.
CYTLIMIC - there are actually 3 phase 1 trials happening - didn't know that  - https://www.cytlimic.com/news/20190809_01_en.html
Two into Liver cancer, one into solid tumours
EOC pharma ph 1 results due next 12 months - any $ coming there?


Quoting from the outlook statement:
"
The second half of FY20 will be a
very important and decisive period for the Company as it plans to report the first PFS data from its late-stage
AIPAC study in metastatic breast cancer. This data is expected in March 2020.

If the data is positive, AIPAC results could help to validate an entirely new class of products in immuno-oncology:
antigen presenting cell activators, along with the “pushing the gas” concept which would be a landmark medical
achievement. It will also arm the Company to make strategic decisions about the development pathway for efti
and pave the way for the creation of very significant value for Immutep and its shareholders.
"
It's all happening - 16 or so trials underway if I counted them correctly, including partners.